Exhaled breath acetone for predicting cardiac and overall mortality in chronic heart failure patients.

ABSTRACT:

Aims

Exhaled breath acetone (EBA) has been described as a new biomarker of heart failure (HF) diagnosis. EBA concentration increases according to severity of HF and is associated with poor prognosis, especially in acute decompensated HF. However, there are no data on chronic HF patients. The aim is to evaluate the role of EBA for predicting cardiac and overall mortality in chronic HF patients.

Methods and results

In GENIUS-HF cohort, chronic patients were enrolled between August 2012 and December 2014. All patients had left ventricular ejection fraction ≤ 50%, and the diagnosis was established according to Framingham criteria. After consent, patients were submitted to clinical evaluation and exhaled breath collection. EBA identification and quantitative determination were do

SUBMITTER: Marcondes-Braga FG 

PROVIDER: S-EPMC7373929 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature